Evogene LTD

Leon Recanati, a Director of Evogene Ltd., purchased 460,000 shares of common stock on August 11, 2026 for $0.64 per share.

L.I.A. Pure Capital Ltd. and associated entities have amended their Schedule 13D filing to report an increase in their beneficial ownership of Evogene Ltd. ordinary shares and ADSs.

Leon Recanati, a board member of Evogene Ltd., has increased his beneficial ownership to 8.6% by acquiring an additional 460,000 ordinary shares.

Leon Recanati, a board member and significant shareholder, has disclosed an increased stake in Evogene Ltd. and declared his intention to vote in favor of the current board's nominees in an upcoming contested director election.

Shareholder group reiterates demand for special meeting and board refreshment, rejecting company's settlement proposals.

L.I.A. Pure Capital Ltd. and affiliated entities have increased their beneficial ownership in Evogene Ltd. to 16.81% through open market purchases of American Depositary Shares.

Major shareholders have formally demanded a special general meeting to replace most of Evogene's board of directors, citing financial underperformance and a need for strategic refreshment.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 713,539 ordinary shares, representing 4.99% of Evogene Ltd.'s outstanding shares.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 9.99% of Evogene Ltd.'s ordinary shares as of March 31, 2026.